ScreenerHero
ABVXABIVAX Société Anonyme
EPA · FR · Healthcare · Biotechnology · abivax.com
101.40EUR+1.30%Mkt Cap: 9.65B $P/E: —

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap9.65B $
Enterprise Value8.14B $
Revenue (TTM)5.35M $
Gross Profit5.35M $
Net Income (TTM)-365.33M $
Revenue/Share0.0728 USD
Last Price101.40 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees80
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012333284
Valuation
P/E (Trailing)—
P/E (Forward)-37.72
PEG—
EV/EBITDA-29.48
EV/Revenue1521.88
P/S1777.00
P/B18.49
EPS (TTM)-4.61
EPS (Forward)-2.66
52W Range
60.4552% of range139.00
52W High139.00 EUR
52W Low60.45 EUR
Profitability
Gross Margin100.00%
Oper. Margin-4183.70%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.84%
ROA-57.52%
Growth
Revenue Growth35.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-175.14M $
CapEx (TTM)154.35K $
FCF Margin-2326.66%
FCF Yield-1.29%
Net Debt-497.11M $
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity0.00
Current Ratio8.25
Quick Ratio8.07
Book Value/Sh5.418 EUR
Cash/Share6.199 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)138.97 EUR
Upside (mean)+37.1%
Target Range70.00 EUR – 180.00 EUR
€70.00+37.1% to mean€180.00
# Analysts6
Ownership
Shares Out.87.25M
Float69.36M
Insiders4.85%
Institutions48.22%
Technical
SMA 50106.80 (-5.1%)
SMA 200103.28 (-1.8%)
Beta-0.23
S&P 52W Chg18.16%
Avg Vol (30d)71.20K
Avg Vol (10d)91.41K
Technical Indicators
RSI (14)35.9
MACD-2.0408
MACD Signal-0.8801
MACD Hist.-1.1606
BB Upper115.15 EUR
BB Middle107.95 EUR
BB Lower100.75 EUR
BB Width13.33%
ATR (14)4.399 EUR
Vol Ratio (20d)0.96x